PAP
INO icon

Persistent Asset Partners’s Inovio Pharmaceuticals INO Stock Holding History

Persistent Asset Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$247K Hold
142,164
– – 0.09% 172
2025
Q4 		$247K Buy
+142,164
New +$313K 0.11% 200

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Persistent Asset Partners's INO Position: Q1 2026 in Review

Persistent Asset Partners held its Inovio Pharmaceuticals (INO) position steady in Q1 2026 at 142,164 shares worth $247K. The position accounts for 0.09% of the portfolio, ranked #172.

Persistent Asset Partners first reported a position in INO in Q4 2025 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Persistent Asset Partners held 142,164 shares of Inovio Pharmaceuticals worth $247K as of Q1 2026.
  • Persistent Asset Partners left its Inovio Pharmaceuticals share count unchanged in Q1 2026.
  • Inovio Pharmaceuticals made up 0.09% of Persistent Asset Partners's portfolio in Q1 2026, its #172 holding.
  • Persistent Asset Partners first reported a position in Inovio Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.